quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 21, 2026

Interactive Brokers signals continued global expansion and record client growth with 1M new accounts in 2025

View original at seekingalpha.com
Interactive Brokers signals continued global expansion and record client growth with 1M new accounts in 2025 Earnings Call Insights: Interactive Brokers Group (IBKR) Q4 2025 MANAGEMENT VIEW * Milan Galik, President and CEO, stated that "in 2025, we added more than 1 million net new accounts, an annual record for the fi…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pretax margin matched the Q3 record of 79% and achieved a new record 77% for the full year 2025

    80% confidence
  • Crypto revenues are small relative to overall company revenues, offering is competitive, and Europe is the current focus for expansion

    80% confidence
  • Commission revenues rose to a record $582 million in Q4 2025

    80% confidence
  • Overall expense growth has been consistent at about 6% growth in headcount, expecting similar growth in the future

    80% confidence
  • Interactive Brokers will not buy a firm that is doing sports betting

    80% confidence
  • Execution, clearing and distribution costs were $91 million in Q4 2025, down 21% from Q4 2024

    80% confidence
  • G&A expenses were $62 million in Q4 2025, up 5% from Q4 2024, driven primarily by advertising

    80% confidence
  • ForecastEx is growing nicely and there is no reason to look for an acquisition in the prediction markets space

    80% confidence
  • Expectation to be operational with bank charter by the end of 2025 if approved

    80% confidence
  • ForecastEx traded 286 million pairs in Q4 2025, up from 15 million pairs in Q3 2025, and now has 4 members quoting into the exchange

    80% confidence
  • Uncertainty exists around regulatory outcomes for prediction markets

    80% confidence
  • European banking license is planned for the future, likely in Ireland, but is not considered urgent

    80% confidence
  • There is no reason why account growth would slow down

    80% confidence
  • Interactive Brokers added more than 1 million net new accounts in 2025, an annual record for the firm

    80% confidence
  • Compensation and benefits expense was $153 million for Q4 2025

    80% confidence
  • Interactive Brokers has not started the European banking license process and it is not urgent

    80% confidence
  • Individual investors were up on average 19.2%, financial advisers were up 20.57% on average, and hedge fund clients were up 28.91% on average in 2025

    80% confidence
  • The bank charter would enable IBKR to custody assets of mutual funds and ETFs

    80% confidence
  • Trading volume during overnight hours is up 76% from last quarter and more than 130% from Q4 2024

    80% confidence
  • Strong performance in margin lending balances overcame the drop in general benchmark rates

    80% confidence
  • Advertising is a key factor and the company is getting better at advertising and increasing spending

    80% confidence
  • Client equity rose 37% to $780 billion, marking the first time the company ended the year with over $0.75 trillion in client assets

    80% confidence
  • Net interest income reached $966 million for Q4 2025 and a yearly record of $3.6 billion despite multiple rate cuts

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Interactive Brokers signals continued global expansion and record client growth with 1M new accounts in 2025 — Source | Via News | pt.VIA.NEWS